DSGN Historical PE Ratio Notes

— Design Therapeutics (NASDAQ: DSGN) is a biotechnology company focused on developing small-molecule therapies for patients with serious degenerative genetic diseases, particularly those caused by nucleotide repeat expansions such as Friedreich ataxia. The company's proprietary GeneTAC platform aims to modulate gene expression and potentially address the underlying causes of these diseases, targeting conditions with limited or no approved treatments. When analyzing historical PE ratio (price-to-earnings ratio) data for DSGN, it's crucial to understand that, as with many clinical-stage biotech firms, Design Therapeutics may not have consistently generated meaningful revenues or positive earnings. This can result in extremely high, undefined, or even negative PE ratios in historical charts & tables, reflecting both high market expectations for future success and the risks associated with the uncertainty of clinical outcomes. Investors in biotech companies like DSGN often focus less on current or trailing PE ratios & more on pipeline progress and anticipated future earnings tied to potential FDA approvals & commercial launches. Therefore, DSGN's historical PE ratios mainly reflect speculation & sentiment around its drug development milestones rather than established earnings power.

On this page we presented the DSGN Historical PE Ratio information for Design Therapeutics' stock. The average DSGN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average DSGN historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this DSGN historical PE result, against the recent PE: when this page was posted on 8/12/2026, the most recent closing price for DSGN had been 14.66, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on DSGN or any other given stock, valuation analysis for DSGN can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Design Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for DSGN. Thanks for visiting, and the next time you need to research DSGN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.